Novo Nordisk A/S (NYSE:NVO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a hold rating to a buy rating in a research note released on Saturday morning.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Guggenheim downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Trading Down 3.5%

Shares of NVO stock opened at $77.02 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a market capitalization of $345.62 billion, a P/E ratio of 23.41, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a 50 day moving average price of $67.61 and a 200 day moving average price of $79.24. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the stock. Cim LLC lifted its position in shares of Novo Nordisk A/S by 4.0% during the 1st quarter. Cim LLC now owns 220,221 shares of the company’s stock worth $15,292,000 after buying an additional 8,398 shares during the last quarter. First Hawaiian Bank lifted its position in shares of Novo Nordisk A/S by 0.6% during the 1st quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock worth $1,556,000 after buying an additional 142 shares during the last quarter. Invst LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $466,000. Modern Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $414,000. Finally, Rhumbline Advisers raised its position in Novo Nordisk A/S by 10.2% in the 1st quarter. Rhumbline Advisers now owns 63,539 shares of the company’s stock valued at $4,412,000 after purchasing an additional 5,898 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.